Todd Rasmussen
Founder

Prytime Medical Devices, Inc. develops the ER-REBOA™ PLUS Catheter, a minimally invasive device that utilizes resuscitative endovascular balloon occlusion of the aorta (REBOA) to temporarily occlude large vessels during non-compressible truncal hemorrhage. This technology addresses the critical need for effective hemorrhage control in trauma situations, significantly improving survival rates in emergency medical settings.
Founder
Founder
Non-compressible truncal hemorrhage is a leading cause of potentially survivable death in trauma patients, yet clinical options for temporarily occluding large vessels during such hemorrhages are limited. Current methods may not provide sufficient control in emergency situations, leading to decreased survival rates.
Prytime Medical Devices develops minimally invasive solutions for hemorrhage control, including the ER-REBOA™ PLUS Catheter. This device utilizes resuscitative endovascular balloon occlusion of the aorta (REBOA) to temporarily occlude large vessels, providing a critical intervention for non-compressible truncal hemorrhage. The ER-REBOA™ PLUS Catheter is designed for rapid deployment in emergency settings, allowing clinicians to quickly gain control of bleeding and improve patient outcomes. REBOA is also used in other emergent hemorrhage control situations, such as postpartum hemorrhage, as an adjunct during surgical procedures and interventional radiology, and in pre-hospital settings.
The primary target audience includes trauma surgeons, emergency physicians, interventional radiologists, and other clinicians involved in managing severe hemorrhage in hospital and pre-hospital settings.